National Cancer Institute, Research Contracts Branch, PCCS, Executive Plaza South, Room 635, Bethesda, MD 20892

A -- MASTER AGREEMENTS FOR PHASE II CLINICAL TRIALS FOR NEW CHEMOPREVENTIVE AGENTS SOL NCI-CN-65001-32 DUE 071495 POC Contact Point, Lance P. Bradley, 301/496-8603, Contracting Officer, Ri chard L. Hartmann, 301/496-8603. The National Cancer Institute is seeking contractors qualified to perform Phase II Clinical Trials that are small short-term, efficient studies of potential chemopreventive agents. This work includes small, short term, efficient studies to determine the dose of given chemopreventive agent that exhibits a pharmacodynamic effect on an intermediate endpoint. These studies will also require dose response studies to determine the minimum dose at the which a biological effect is observed and confirmation of the maximum safe dose, and the performance of randomized blinded trials in small groups of subjects whose endpoints will be the measurable biological effect of the agent versus a placebo. The solicitaion is an annual announcement expand a current pool of Master Agreement (MA) Holders qualified to perform this type of work. Individual work requirements will be defined, as the need arises, by Master Agreement Orders issued during the period of performance, and Master Agreement Orders will be awarded based upon competition between members of the MA pool. The RFP is expected to be released May 12, 1995, with proposals due July 14, 1995. Copies of the RFP may be obtained by sending a written request to: Ms. Desiree Sylver-Foust, Procurement Technician, PCCS, RCB, OD, NCI, Executive Plaza South, Suite 635 MSC 7226, 9000 Rockville Pike Bethesda, Maryland 20892-7226. No collect calls will be accepted. (0109)

Loren Data Corp. http://www.ld.com (SYN# 0003 19950420\A-0003.SOL)